ZLZhixuan Lan

Zhixuan Lan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhixuan Lan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Ruilin He

    Department of Pain Management, The Second Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

    2 shared publications
  • Zongbin Jiang

    Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China

    2 shared publications
  • Kan Yue

    Department of Pain Medicine The First Affiliated Hospital of Bengbu Medical University Bengbu People's Republic of China

    1 shared publication
  • Liu Wang

    Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530007, People's Republic of China

    1 shared publication
  • Xiaoxiao Lan

    Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530007, People's Republic of China

    1 shared publication
  • Xin Hu

    Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530007, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Digital Cognitive Behavioral Therapy for Insomnia in Cancer Pain Patients: Protocol for a Prospective, Randomized Controlled Trial

    by Xiaoxiao Lan, Xin Hu, Zhixuan Lan, Liu Wang, Ruilin He, Zongbin Jiang

    Introduction: Insomnia is one of the most common complications in cancer patients, and Cognitive Behavioral Therapy for Insomnia (CBT-I) is the first-line treatment for insomnia in the general population and patients with a cancer diagnosis. Traditional CBT-I is susceptible to limitations such as geography, physical condition, and cost of access to healthcare, hindering its widespread adoption. With the application and development of digitalization and artificial intelligence providing opportunities for the administration and promotion of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) to provide a better sleep treatment option for cancer pain patients, this study aims to evaluate its efficacy. Methods: This single-center trial will randomize 158 cancer pain patients with insomnia to DCBT-I or sleep hygiene education (1:1) to test if DCBT-I is superior for improving sleep quality. Assessments will also cover pain intensity, mental health, and quality of life. Discussion: This study will provide valuable clinical evidence that DCBT-I helps to improve sleep quality, pain intensity, mental health, and quality of life in cancer pain patients suffering from insomnia and contributes to the dissemination of this non-pharmacological alternative treatment option. Conclusion: This study protocol outlines a rigorous randomized controlled trial to evaluate the efficacy of Digital Cognitive Behavioral Therapy for Insomnia (DCBT-I) compared to Sleep Hygiene Education (SHE) in cancer pain patients with comorbid insomnia. The Resleep smartphone-based intervention integrates evidence-based CBT-I components (sleep restriction, stimulus control, cognitive restructuring, and relaxation training) to address the limitations of traditional therapy, such as accessibility and cost. Clinical Trial Registration: This study is a registered clinical trial. Registry: Chinese Clinical Trial Registry (ChiCTR), listed in the WHO International Clinical Trials Registry Platform (WHO ICTRP). Trial Registration Number: ChiCTR2500096855. Date of Registration: 07 February 2025. Registration Url: https://www.chictr.org.cn/index.html.

  • Open Access

    Genetically predicted immune cells mediate the association between gut microbiota and neuropathy pain

    by Zhixuan Lan, Yi Wei, Kan Yue, Ruilin He, Zongbin Jiang

    Background: Previous observational studies have indicated a complex association between gut microbiota (GM) and neuropathic pain (NP). Nonetheless, the precise biological mechanisms underlying this association remain unclear. Therefore, we adopted a Mendelian randomization (MR) approach to investigate the causal relationship between GM and neuropathic pain including post-herpetic neuralgia (PHN), painful diabetic peripheral neuropathy (PDPN), and trigeminal neuralgia (TN), as well as to explore the potential mediation effects of immune cells. Methods: We performed a two-step, two-sample Mendelian randomization study with an inverse variance-weighted (IVW) approach to investigate the causal role of GM on three major kinds of NP and the mediation effect of immune cells between the association of GM and NP. In addition, we determine the strongest causal associations using Bayesian weighted Mendelian randomization (BWMR) analysis. Furthermore, we will investigate the mediating role of immune cells through a two-step Mendelian randomization design. Results: We identified 53 taxonomies and pathways of gut microbiota that had significant causal associations with NP. In addition, we also discovered 120 immune cells that exhibited significant causal associations with NP. According to the BWMR and two-step Mendelian randomization analysis, we identified the following results CD4 on CM CD4 + (maturation stages of T cell) mediated 6.7% of the risk reduction for PHN through the pathway of fucose degradation (FUCCAT.PWY). CD28 + DN (CD4-CD8-) AC (Treg) mediated 12.5% of the risk reduction for PHN through the influence on Roseburia inulinivorans. CD45 on lymphocyte (Myeloid cell) mediated 11.9% of the risk increase for TN through the superpathway of acetyl-CoA biosynthesis (PWY.5173). HLA DR + CD8br %T cell (TBNK) mediated 3.2% of the risk reduction for TN through the superpathway of GDP-mannose-derived O-antigen building blocks biosynthesis (PWY.7323). IgD-CD38-AC (B cell) mediated 7.5% of the risk reduction for DPN through the pathway of thiazole biosynthesis I in E. coli (PWY.6892). Discussion: These findings provided evidence supporting the causal effect of GM with NP, with immune cells playing a mediating role. These findings may inform prevention strategies and interventions directed toward NP. Future studies should explore other plausible biological mechanisms.